Aquestive therapeutics reaffirms timeline and pathway for anaphylm™ (epinephrine) sublingual film

Warren, n.j., sept. 20, 2023 (globe newswire) -- aquestive therapeutics, inc. (nasdaq:aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, anaphylm™.
AQST Ratings Summary
AQST Quant Ranking